Omeicos Therapeutics, a Berlin, Germany-based biopharmaceutical company, raised €6.2m in Series A round.
The round was led by Vesalius Biocapital II S.A. SICAR, with participation from SMS Group, VC Fonds Technologie Berlin; Hightech Gruenderfonds II GmbH & Co. KG (HTGF); and KfW Group. As part of the financing round, the company has received €550k via Ascenion’s Spinnovator, a grant program supported by the German Ministry of Education and Research (BMBF). Following the closing of the financing round, Christian Schneider and Gaston Matthyssens of Vesalius Biocapital Partners, Peter Seiler of SMS Group, Ute Mercker of VC Fonds Technologie Berlin, Martin Pfister of Hightech Gruenderfonds II GmbH & Co. KG, and co-founder Wolf-Hagen Schunck have joined the OMEICOS Supervisory Board.
Omeicos Therapeutics is a spin-off company from the Max Delbrueck Center for Molecular Medicine (MDC) in Berlin, co-founded and managed by Dr. Robert Fischer (Managing Director) and Dr. Karen Uhlmann. The company is developing oral small molecules for the prevention and treatment of cardiovascular diseases, initially focusing on AF. Its small molecule AF therapy is based on proprietary synthetic analogues of omega-3 fatty acid metabolites.
Omeicos lead candidate is envisioned for oral, once-daily treatment for patients with paroxysmal and persistent AF, with and without structural heart disease, for maintenance of sinus rhythm.